Anzeige
Mehr »
Login
Mittwoch, 22.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die Wachstumsgeschichte: Analysten sehen kurzfristige +37 %-Chance bei diesem europäischen Marktführer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EB9V | ISIN: CA60256C1086 | Ticker-Symbol: WF6
Tradegate
17.05.24
17:55 Uhr
0,050 Euro
+0,012
+32,45 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MINDBIO THERAPEUTICS CORP Chart 1 Jahr
5-Tage-Chart
MINDBIO THERAPEUTICS CORP 5-Tage-Chart
RealtimeGeldBriefZeit
0,0270,04821.05.
0,0000,00021.05.

Aktuelle News zur MINDBIO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.05.Enveric Biosciences to out-license psilocin prodrug to MindBio6
14.05.Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders182MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic compoundsVANCOUVER, BC / ACCESSWIRE /...
► Artikel lesen
14.05.Mindbio Therapeutics Corp: Mindbio signs term sheet for Enveric psilocin prodrugs4
14.05.Enveric Biosciences signs $66.5M non-binding term sheet with MindBio Therapeutics2
02.05.MindBio Therapeutics Scientists Present Landmark Women's Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month278VANCOUVER, BC / ACCESSWIRE / May 2, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a clinical stage biopharma company pioneering microdosing treatments for...
► Artikel lesen
01.05.Mindbio Therapeutics Corp: Mindbio mulls dual listing, in talks for phase 3 trials4
01.05.MindBio Therapeutics: MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3333VANCOUVER, BC / ACCESSWIRE / May 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), is pleased to announce that it has been presenting MindBio to various parties...
► Artikel lesen
30.04.Mindbio Therapeutics Corp: Mindbio cleared to test menstrual cycle response to LSD2
30.04.MindBio Therapeutics Announces Landmark Women's Health CNS Drug Trials205ASSESSING THE EFECTS OF MICRODOSING MB22001 IN MENSTRUATING PERSONS WITH AND WITHOUT PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER Multiple clinical trials in women's health approved for...
► Artikel lesen
23.04.MindBio Therapeutics: MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry181MindBio scientist's sleep research published in prestigious peer reviewed scientific journalMindBio's proprietary treatment protocol using MB22001, results in longer sleep and better quality of sleep...
► Artikel lesen
16.04.Mindbio Therapeutics Corp: Mindbio lender opts for shares in lieu of cash4
16.04.MindBio Therapeutics: Lender Requests to Convert Loan to MindBio Shares198VANCOUVER, BC / ACCESSWIRE / April 16, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio") is pleased to announce Riverfort Global Opportunities PCC Ltd has requested...
► Artikel lesen
20.03.Mindbio Therapeutics Corp: Mindbio begins first dosing in phase 2B MB22001 trial4
20.03.MindBio Therapeutics: MindBio Begins Landmark Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder204First doses of MB22001 administered in Phase 2B take-home trial in patients with Major Depressive Disorder.Follows successful Phase 2A trial where 53% of depressed patients were in complete remission...
► Artikel lesen
04.03.Mindbio Therapeutics Corp: Mindbio receives final approval for phase 2B LSD trial6
04.03.MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder240Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-controlled trial in depressed patients n=90Recruitment of clinical trial participants...
► Artikel lesen
26.02.Mindbio Therapeutics Corp: Mindbio releases data from phase 2a LSD clinical trial8
26.02.MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial233MindBio demonstrates safe, effective take home use of MB22001 in Depressed patients over an 8-week, world first take-home trialRapid, robust, and clinically significant reduction in depression symptomsPrimary...
► Artikel lesen
14.02.Mindbio Therapeutics Corp: Mindbio completes phase 2a LSD clinical trial7
14.02.MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial419VANCOUVER, BC / ACCESSWIRE / February 14, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharma company in psychiatric medicine development,...
► Artikel lesen
Seite:  Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1